Clinical Trial Update: Rilonacept in Subjects With Cardiac Sarcoidosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating rilonacept (Arcalyst) for cardiac sarcoidosis and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Sarcoidosis

Drugs mentioned

• Arcalyst (rilonacept)

Snippet

Sponsor: Mayo Clinic | Conditions: Cardiac Sarcoidosis | Phase 2 | Status: RECRUITING